|
| Tuesday, November 24, 2015 |
|
|
Uni-Bio Science Acquires Global Rights to Type 2 Diabetes Drug Mitiglinide from Jiangsu Hansoh Pharmaceutical Co. Ltd |
Uni-Bio Science Group Limited ("Uni-Bio" or the "Group"; HKEx code: 690) today announced that it will acquire exclusive global rights to manufacture and commercialise mitiglinide, a new oral antidiabetic agent, from Jiangsu Hansoh Pharmaceutical Co. Ltd ("Hansoh").
more info >> |
|
| Tuesday, September 8, 2015 |
|
|
联康生物科技集团位于北京之化学药品生产线成功通过GMP 2010认证 |
联康生物科技集团有限公司（「联康生物科技」或「集团」）（股份代号：0690）欣然宣布，其位于北京之化学药品生产线已成功通过《药品生产质量管理规范（2010 年修订）》 （「GMP 2010」）之检查，并于二零一五年八月十七日获得由国家食品药品监督管理总局（「国家食药监总局」）发出之《药品GMP证书》。
more info >> |
|
|
聯康生物科技集團位於北京之化學藥品生產線成功通過GMP 2010認證 |
聯康生物科技集團有限公司（「聯康生物科技」或「集團」）（股份代號：0690）欣然宣佈，其位於北京之化學藥品生產線已成功通過《藥品生產質量管理規範（2010 年修訂）》（「GMP 2010」）之檢查，並於二零一五年八月十七日獲得由國家食品藥品監督管理總局（「國家食藥監總局」）發出之《藥品GMP證書》。
more info >> |
|
|
Uni-Bio Science Group's Chemical Manufacturing Line in Beijing Passes GMP 2010 Standard |
Uni-Bio Science Group Limited ("Uni-Bio Science" or the "Group;" HKEx code: 690) is pleased to announce that the Group's chemical manufacturing line in Beijing has successfully passed the inspection under "Good Manufacturing Practice (2010 revision)"("GMP 2010") and received the Certificate of GMP for pharmaceutical products issued by China Food and Drug Administration ("CFDA") on 17 August 2015.
more info >> |
|
| Friday, August 14, 2015 |
|
|
联康生物科技集团公布二零一五年中期业绩 |
| 联康生物科技集团有限公司（「联康生物科技」或「集团」）（股份代号：0690）宣布截至二零一五年六月三十日止六个月之中期业绩。 more info >> |
|
|
聯康生物科技集團公佈二零一五年中期業績 |
| 聯康生物科技集團有限公司（「聯康生物科技」或「集團」）（股份代號：0690）宣佈截至二零一五年六月三十日止六個月之中期業績。 more info >> |
|
|
Uni-Bio Science Group Announces 2015 Interim Results |
| Uni-Bio Science Group Limited ("Uni-Bio Science" or the "Group;" HKEx code: 690) has announced its interim results for the six months ended 30 June 2015. Following the bolstering of the sales and marketing teams and the Medical Function last year more info >> |
|
| Monday, August 3, 2015 |
|
|
联康生物科技宣布用于治疗2型糖尿病的Uni-E4 III期临床试验效果良好 |
| 联康生物科技集团有限公司（「联康生物科技」或「集团」）（股份代号：0690）今天宣布，III期临床实验重组艾塞那肽-4（「Uni-E4」）（集团用于治疗2型糖尿病的专利药物，重组GLP-1 受体激动剂）有良好的疗效和安全性。 more info >> |
|
|
聯康生物科技宣佈用於治療2型糖尿病的Uni-E4 III期臨床試驗效果良好 |
| 聯康生物科技集團有限公司（「聯康生物科技」或「集團」）（股份代號：0690）今天宣佈，III期臨床實驗重組艾塞那肽-4（「Uni-E4」）（集團用於治療2型糖尿病的專利藥物，重組GLP-1 受體激動劑）有良好的療效和安全性。 more info >> |
|
|
Uni-Bio Science Group Announces Positive Phase III Results for Uni-E4 in Type-2 Diabetes |
| Uni-Bio Science Group Limited ("Uni-Bio" or the "Group";HKEx code: 690) today announced positive top-line results of the Phase III clinical trial which assessed the efficacy and safety of Uni-E4, Uni-Bio's proprietary recombinant GLP-1 receptor agonist for the treatment of Type-2 diabetes. more info >> |
|
|
|
|
